Expecting Massive Test Growth in Cancer & More, Tempus AI Strikes $1.5B Deal to Buy Personalis

Tempus AI announced a $1.5 billion acquisition of Personalis, a liquid biopsy company specializing in minimal residual disease (MRD) assays that detect remaining cancer cells after treatment. Tempus has served as the commercial partner for Personalis's MRD test since 2023. The deal consolidates two players in the growing cancer diagnostics market.